SUMMARY Plasma antithrombin activity was measured using an amidolytic method (substrate Chromozym TH) and a clotting method. The mean antithrombin values found in 76 hospital outpatients were 9 4 jtmol/min/ml with the amidolytic procedure and 100-1 % of antithrombin activity with the clotting procedure. The two methods correlate fairly well (r = 0-85, P < 0 01) and show satisfactory reproducibility. Coefficients of variation of 5 9 % and 8 8 % were obtained respectively with the amidolytic and the clotting procedures. In the presence of very high levels of fibrinogen degradation products, falsely elevated antithrombin activity levels were observed with the clotting procedure but the amidolytic method is essentially unaffected. It is concluded that both methods are suitable for determining antithrombin activity but a well-standardised amidolytic procedure has advantages.
It is now generally accepted that antith rombin-III is the principal natural inhibitor of thrombin and factor Xa (Biggs et al., 1970; Yin et al., 1971) . The inhibitor and thrombin or factor Xa form a stable 1:1 stoichiometric complex ; in the absence of heparin the reaction is slow and progressive, but the addition of heparin greatly accelerates the rate of formation of the complex, probably by inducing a conformational change in the inhibitor molecule Villanueva and Danishefsky, 1977) . Antithrombin-III also has the property of neutralising virtually all the serine proteases of the coagulation and fibrinolytic system even if inactivation occurs at characteristically slow rates compared with that of thrombin and factor Xa Highsmith and Rosenberg, 1974; 0sterud et al., 1976) .
From these observations it has become evident that the inhibitory action of antithrombin-III is a very important feedback mechanism in the regulation of haemostatic balance and its physiological significance is further stressed by the recognition that low levels of antithrombin-III are associated with recurrent thromboembolic disease. Congenital deficiency of antithrombin-III is a rare event, probably inherited as an autosomal dominant trait, which affects both sexes equally (Egeberg, 1965; van der Received for publication 23 June 1978 Meer et Sas et al., 1974; Marciniak et al., 1974; Carvalho and Ellman, 1976; 0degard and Abildgaard, 1977) . More frequently, a low concentration of antithrombin-III is secondary to liver disease or due to consumption as during disseminated intravascular coagulation or heparin therapy (von Kaulla and von Kaulla, 1967; Collen et al., 1977) . Reduced antithrombin-III has also been reported in women using oral contraceptives (Zuck et al., 1971) .
Antithrombin-III level is thus a fundamental parameter for the assessment of a 'coagulation profile'. The procedures currently employed for antithrombin-III determination are immunological or functional. Both give essentially corresponding results, but the functional assay should be preferred for two reasons: the speed of the test performance and the possibility that apparently normal antithrombin-III concentration may be associated with a low inhibitory activity (Sas et al., 1974) . Until now the basis of every functional assay has been the progressive neutralisation of the clotting activity of thrombin by serum or defibrinated plasma. Recently, however, the availability of chromogenic substrates for thrombin and factor Xa has led to the development of amidolytic methods for the measurement of antithrombin activity (Blomback et al., 1974; 0degard et al., 1975 Triethanolamine buffer, pH 8.4, containing heparin 3 U/ml was prepared by dissolving 18-57 g of triethanolamine HCl and 11.69 g of NaCl in 800 ml of distilled water; the pH was adjusted with 2 N NaOH, and heparin (Novo Heparin, 5000 U/mi, lot 32-17) was added before making up to 1 litre.
Thrombin solution, 10 U/ml, was obtained by reconstituting Fibrindex (Ortho Diagnostics, 50 NIH U/vial, lot ION215) with isotonic saline. Albumin stock solution was prepared by dissolving 4 g of bovine serum albumin (Behringwerke) in isotonic saline.
ASSAY PROCEDURE
Of the working thrombin solution, 0-1 ml is added to 0 4 ml of test plasma diluted 100-fold with buffer. An interval timer is started, and, after 30 seconds, the amidolytic reaction is initiated by delivering 0-2 ml of chromogenic substrate in the plasma-thrombin mixture. The reaction, performed at 370C, is stopped after exactly 30 seconds by adding 0'3 ml of concentrated acetic acid. Absorbance at 405 nm is read against a blank containing 0'4 ml of diluted plasma, 0 3 ml of distilled water, and 0 3 ml of concentrated acetic acid. By the same procedure is A. Frigola, S. Angeloni, and Anna Rita Cerqueti obtained the absorbance produced by thrombin alone, plasma being substituted by the albumin stock solution diluted 100-fold with buffer.
The plasma antithrombin activity (PATA) is expressed as amount of thrombin amidolytic activity inhibited (measured by the difference between the amidolytic activity of thrombin alone and that of thrombin plus test plasma) using the following formula:
PATA (,umol/min/ml) = A Vt E VP t where z A is the difference between the absorbance of the albumin-thrombin mixture and that of plasmathrombin mixture, Vt is the assay volume in microlitres, Vp is the plasma added in microlitres, e is the molar extinction coefficient of p-NA, and t is the assay time in minutes. With a light pathway of 1 cm, Vt = 1000
Ia, Vp = 4 ILI, e = 9 9 1 mmolcm-1, and t = 0 5 min, the equation reduces to:
PATA (,umol/min/ml) = 50 5 *A A Linearity of inhibition at different antithrombin-III plasma concentrations was investigated using 1:50, 1:75, 1:100, and 1:200 dilutions of pooled plasma in buffer with heparin. zl A was plotted against the percentage of antithrombin activity, assuming as 100% that of the 1:100 plasma dilution. The relation obtained (Fig. 1) was a straight line which passes through the origin. The procedure employed was performed as previously described (Frigola, 1977) except that serum was substituted by defibrinated plasma. Defibrination was obtained by adding 01 ml of Reptilase (Lepetit, Milan, lot 1123), a thrombin-like enzyme from the venom of Bothrops atrox, to 0 5 ml of test plasma. After 10 minutes at room temperature the fibrin was removed by high-speed centrifugation, and plasma was diluted 1:5 with Tris-saline solution (0 154 M NaCI, 0-2 M Tris buffer, pH 7 4). The defibrination step does not minimally affect the method linearity even if the precision is slightly reduced (coefficients of variation, respectively, of 2-7% using serum and of 8-8y using defibrinated plasma).
PREPARATION OF FIBRINOGEN DEGRADATION PRODUCTS (FDPS)
To study the interference of FDPs on antithrombin activity assay, an 'in vitro' plasmin digest of fibrinogen was prepared by adding Streptokinase (Streptase, Behringwerke, lot 673A) 100 U/ml final concentration to a human fibrinogen solution (Immuno, Vienna, lot 040277, 10 mg/ml). The reaction performed at 37°C was stopped at different times with 0-2 M E-aminocaproic acid (final concentration). Characterisation of FDPs was performed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis on 4% gel (Fig. 2) and by densitometric analysis.
Results
The mean values for antithrombin activity found in the population under study, by the amidolytic and clotting procedures, are reported in Figure 3 . The precision of the amidolytic and clotting procedures was evaluated by performing respectively 27 and 24 replicate determinations on the same plasma pool; the results are reported in Table 2 . The interference by FDPs with antithrombin assay was assessed by adding, in the fixed volumetric ratio of 1:1, the different fibrinogen digests to the same plasma pool containing 0-2 M e-aminocaproic acid in final concentration. The resulting antithrombin activity levels were determined by both procedures with reference to a control plasma to which Trissaline solution pH 7-4 and 0-2 M E-aminocaproic acid in final concentration were added (Table 3) (Machovich et al., 1977) , increase assay specificity. Another interesting feature, shown by the amidolytic procedure, is that antithrombin activity is expressed in a true quantitative way (,umol/min/ml) rather than as a percentage of activity.
There are also some limitations: the cost per assay is at present higher than with the clotting procedure, and the test performance is rather complicated. Furthermore, since the key step in thrombin inactivation is a complex formation with antithrombin-III ) the use of native thrombin is fundamental for the reliability of antithrombin assay by functional methods. However, using the amidolytic assay, it is difficult to recognise the presence of denatured thrombin in that there are structural changes in the enzyme molecule which lead to the loss of the clotting activity without any detectable modification in amidolytic activity (Gaffney et al., 1977) . Thus, the clotting activity of every thrombin preparation should be checked before every amidolytic assay, mainly if thrombin has been stored after reconstitution.
The clotting method is satisfactorily precise and has the advantages of technical simplicity and relatively low cost. The principal drawback is its sensitivity to FDPs. However, it should be stressed that FDP concentrations as high as those used in our experiments (above 1000 ug/ml) can be detected only in patients undergoing thrombolytic treatment for deep-vein thrombosis. At FDP levels under 100 gg/ml, as commonly found in acute and chronic disseminated intravascular coagulation, the accuracy of the clotting procedure method is not significantly affected. 
